Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.

Petros Z, Lee MM, Takahashi A, Zhang Y, Yimer G, Habtewold A, Amogne W, Aderaye G, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E.

BMC Genomics. 2016 Sep 26;17(1):755.

2.

Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.

Aseffa A, Chukwu JN, Vahedi M, Aguwa EN, Bedru A, Mebrahtu T, Ezechi OC, Yimer G, Yamuah LK, Medhin G, Connolly C, Rida W, Aderaye G, Zumla AI, Onyebujoh PC; 4FDC Study Group.

PLoS One. 2016 Jun 20;11(6):e0157434. doi: 10.1371/journal.pone.0157434. eCollection 2016.

3.

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, Aklillu E, Makonnen E, Aderaye G, Roach J, Fier I, Kampf C, Göpfert J, Perazzo H, Poynard T, Stephens C, Andrade RJ, Lucena MI, Arber N, Uhlén M, Watkins PB, Schwenk JM, Nilsson P, Schuppe-Koistinen I.

Liver Int. 2016 May 25. doi: 10.1111/liv.13174. [Epub ahead of print]

PMID:
27224670
4.

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J.

J Clin Pharmacol. 2016 Apr 29. doi: 10.1002/jcph.756. [Epub ahead of print]

PMID:
27125860
5.

Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster.

Amogne W, Bontell I, Grossmann S, Aderaye G, Lindquist L, Sönnerborg A, Neogi U.

AIDS Res Hum Retroviruses. 2016 May;32(5):471-4. doi: 10.1089/aid.2015.0380. Epub 2016 Feb 16.

PMID:
26881451
6.

Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.

Meressa D, Hurtado RM, Andrews JR, Diro E, Abato K, Daniel T, Prasad P, Prasad R, Fekade B, Tedla Y, Yusuf H, Tadesse M, Tefera D, Ashenafi A, Desta G, Aderaye G, Olson K, Thim S, Goldfeld AE.

Thorax. 2015 Dec;70(12):1181-8. doi: 10.1136/thoraxjnl-2015-207374. Epub 2015 Oct 27.

7.

Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, Sonnerborg A, Aklillu E, Lindquist L.

PLoS One. 2015 May 12;10(5):e0122587. doi: 10.1371/journal.pone.0122587. eCollection 2015.

8.

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.

9.

Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR.

Ekici H, Amogne W, Aderaye G, Lindquist L, Sönnerborg A, Abdurahman S.

PLoS One. 2014 Oct 21;9(10):e111042. doi: 10.1371/journal.pone.0111042. eCollection 2014.

10.

Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.

Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, Aderaye G, Schuppe-Koistinen I, Lindquist L, Aklillu E.

PLoS One. 2014 Apr 8;9(4):e94271. doi: 10.1371/journal.pone.0094271. eCollection 2014.

11.

Progression of clinical tuberculosis is associated with a Th2 immune response signature in combination with elevated levels of SOCS3.

Ashenafi S, Aderaye G, Bekele A, Zewdie M, Aseffa G, Hoang AT, Carow B, Habtamu M, Wijkander M, Rottenberg M, Aseffa A, Andersson J, Svensson M, Brighenti S.

Clin Immunol. 2014 Apr;151(2):84-99. doi: 10.1016/j.clim.2014.01.010. Epub 2014 Feb 9.

12.

Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa.

Machado LR, Bowdrey J, Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Yimer G, Amogne W, Mugusi S, Janabi M, Aderaye G, Mugusi F, Viskaduraki M, Aklillu E, Hollox EJ.

PLoS One. 2013 Nov 8;8(11):e78165. doi: 10.1371/journal.pone.0078165. eCollection 2013.

13.

CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans.

Aklillu E, Odenthal-Hesse L, Bowdrey J, Habtewold A, Ngaimisi E, Yimer G, Amogne W, Mugusi S, Minzi O, Makonnen E, Janabi M, Mugusi F, Aderaye G, Hardwick R, Fu B, Viskaduraki M, Yang F, Hollox EJ.

BMC Infect Dis. 2013 Nov 12;13:536. doi: 10.1186/1471-2334-13-536.

14.

Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.

Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, Aderaye G, Lindquist L, Mattsson CM, Ekblom B, Antoine DJ, Park BK, Linder S, Harrill AH, Watkins PB, Glinghammar B, Schuppe-Koistinen I.

Liver Int. 2014 Mar;34(3):367-78. doi: 10.1111/liv.12322. Epub 2013 Oct 14.

PMID:
24118944
15.

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J.

PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013.

16.

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.

Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Pharmacogenomics J. 2013 Dec;13(6):484-9. doi: 10.1038/tpj.2012.46. Epub 2012 Oct 23.

PMID:
23089673
17.

BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients.

Ashenafi S, Aderaye G, Zewdie M, Raqib R, Bekele A, Magalhaes I, Lema B, Habtamu M, Rekha RS, Aseffa G, Maeurer M, Aseffa A, Svensson M, Andersson J, Brighenti S.

Thorax. 2013 Mar;68(3):269-76. doi: 10.1136/thoraxjnl-2012-201817. Epub 2012 Aug 24.

18.

β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans.

Hardwick RJ, Amogne W, Mugusi S, Yimer G, Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Janabi M, Machado LR, Viskaduraki M, Mugusi F, Aderaye G, Lindquist L, Hollox EJ, Aklillu E.

J Infect Dis. 2012 Oct 1;206(7):1012-9. doi: 10.1093/infdis/jis448. Epub 2012 Jul 26.

19.

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E.

PLoS One. 2011;6(12):e27810. doi: 10.1371/journal.pone.0027810. Epub 2011 Dec 6.

20.

Clinical characterization of sarcoidosis in Ethiopia.

Diro E, Atnafu A, Aleme M, Aderaye G.

Ethiop Med J. 2011 Oct;49(4):323-9.

PMID:
23409397
Items per page

Supplemental Content

Loading ...
Write to the Help Desk